Correction to: Allergy Asthma Clin Immunol (2019) 15:72 10.1186/s13223-019-0376-8
Following the publication of this article [1], the authors requested to amend the characterisation of ‘lanadelumab’ from ‘humanised’ to the correct ‘fully human’.
Therefore, the fourth paragraph under Recommendation #24 should be amended to read:
“Lanadelumab (Takeda), a fully human monoclonal antibody against kallikrein, takes approximately 70 days to reach a steady state concentration [110], and is therefore not recommended for STP…”
Similarly, the first paragraph under Recommendation #27 should be amended to read:
“Lanadelumab is a subcutaneously injectable, fully human, anti-active plasma kallikrein monoclonal antibody (IgG1/κ-light chain)…”
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Reference
- 1.Betschel S, Badiou J, Binkley K, Borici-Mazi R, Hébert J, Kanani A, Keith P, Lacuesta G, Waserman S, Yang B, Aygören-Pürsün E, Bernstein J, Bork K, Caballero T, Cicardi M, Craig T, Farkas H, Grumach A, Katelaris C, Longhurst H, Riedl M, Zuraw B, Berger M, Boursiquot J, Boysen H, Castaldo A, Chapdelaine H, Connors L, Lisa F, Goodyear D, Haynes A, Kamra P, Kim H, Lang-Robertson K, Leith E, McCusker C, Moote B, O’Keefe A, Othman I, Poon M, Ritchie B, St-Pierre C, Stark D, Tsai E. The International/Canadian Hereditary Angioedema Guideline. Allergy Asthma Clin Immunol. 2019;15:72. doi: 10.1186/s13223-019-0376-8. [DOI] [PMC free article] [PubMed] [Google Scholar]